A Phase 3 interventional study of Immune Globulin Intravenous (human), 10% and 0.25% human albumin solution (Placebo) in Multifocal Motor Neuropathy, sponsored by Baxalta now part of Shire. Completed at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the efficacy (effect on grip strength and disability) and safety/tolerability of IGIV, 10% in subjects with Multifocal Motor Neuropathy.
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
First submitted before Baxalta became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: IGIV, 10% (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human)(Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3). Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg body weight (BW) per infusion cycle).
Biological: Immune Globulin Intravenous (human), 10% · Biological: 0.25% human albumin solution (Placebo)
STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human) (Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: IGIV, 10% (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3). Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg BW per infusion cycle)
Biological: Immune Globulin Intravenous (human), 10% · Biological: 0.25% human albumin solution (Placebo)
Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
Also known as: IGIV, 10%, GAMMAGARD LIQUID, KIOVIG
Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
Also known as: BUMINATE 25%, Albumin (Human) Solution, Human Albumin 200 g/L Baxter
Grip Strength in the More Affected Hand
The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. Each grip strength test consisted of 3 maximal repeated contractions (trials). Each participant will perform 2 sessions of grip strength testing. After a 10-minute break, the testing session will be repeated for a total of 6 grip repetitions per hand.
Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Mean Relative Change in Grip Strength in the More Affected Hand
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.
Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Co-Primary Endpoint: Guy's Neurologic Disability Scale (GNDS) for Upper Limbs
GNDS (based on Sharrack and Hughes, 1999) for the upper limbs were integers 0 to 5, with 0 indicating no impairment.
Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Co-Primary Endpoint: Proportion of Participants With Deterioration in Guy's Neurological Disability Score (GNDS)
GNDS (based on Sharrack and Hughes, 1999) for the upper limbs were integers 0 to 5, with 0 indicating no impairment.
Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Rate of Temporally Associated Adverse Events (AEs) Per Infusion
The total number of all AEs which begin during or within 72 hours of completion of an infusion, irrespective of being related or not related to the study product (IGIV, 10% or Placebo), divided by the total number of infusions, and multiplied by 100.
Time frame: Within 72 hours of completion of an infusion during the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
The Percentage of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason
Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
The Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason
Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
The Percentage of Participants Reporting One or More Moderate or Severe AEs That Began During Infusion or Within 72 Hours of Completion of an Infusion
Time frame: Within 72 hours of completion of an infusion during the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Percentage of Participants With at Least a 30% Decline in Relative Grip Strength in the More Affected Hand (Measured Using a DynEx Digital Dynamometer)
Relative grip strength change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.
Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Grip Strength in the Less Affected Hand
The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. Each grip strength test consisted of 3 maximal repeated contractions (trials). Each participant will perform 2 sessions of grip strength testing. After a 10-minute break, the testing session will be repeated for a total of 6 grip repetitions per hand.
Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Mean Relative Change in Grip Strength in the Less Affected Hand
Relative Change is defined as 100 \* (End of the Cross-Over Period - Baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.
Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Proportion of Participants That Were Accelerated Forward Into the Next Stabilization Phase (ie Switched to Open-Label IGIV, 10%)
Participants were permitted to switch from blinded treatment with placebo or IGIV, 10% to open label IGIV, 10% if they and investigator agreed that deterioration had occurred to the extent that the participant had unacceptable difficulty carrying out daily activities involving the affected muscles, or decline in grip strength of ≥50% in the more affected hand had occurred.
Time frame: During the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Patient Global Impression of Change
Patient Global Impression of Change was measured on an ordinal scale of 1-7, higher scores representing greater perceived deterioration since the previous efficacy assessment (ranging from (1) very much improved to very much worse (7)). 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse
Time frame: Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Overall Disability Sum Score
The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability. Overall disability sum score = arm disability scale (range 0-5) + leg disability scale (range 0-7); Overall Range: 0 (no signs of disability) to 12 (maximum disability).
Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Overall Disability Sum Score - Standardized
The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability. Overall disability sum score = arm disability scale (range 0-5) + leg disability scale (range 0-7); Overall Range: 0 (no signs of disability) to 12 (maximum disability). This was standardized to a scale of 0 to 100 (the best score being 100) to allow calculation of relative changes.
Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Mean Relative Change in Overall Disability Sum Score
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability (from 0, "no signs of disability" to 12, "most severe disability"). This was standardized to a scale of 0 to 100 (the best score being 100) to allow calculation of relative changes.
Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand
The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.
Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.
Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand
The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their non-dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.
Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their non-dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.
Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Participants' Assessment of Physical Functioning on a Visual Analog Scale (VAS)
The VAS measured patients' assessment of physical functioning on a 10 centimeter scale of 0-10, on which 0 represents "no symptoms" and 10 "disabled, unable to use affected limbs".
Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Mean Relative Change in Participants' Assessment of Physical Functioning on a Visual Analog Scale (VAS)
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The VAS measured patients' assessment of physical functioning on a 10 centimeter scale of 0-10, on which 0 represents "no symptoms" and 10 "disabled, unable to use affected limbs".
Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Rate of Related AEs Per Infusion
The total number of AEs determined by the investigator to be related to the study product that occur at any time during the study divided by the total number of infusions, and multiplied by 100.
Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Rate of Related SAEs Per Infusion
The total number of SAEs determined by the investigator to be related to the study product that occur at any time during the study divided by the total number of infusions, and multiplied by 100.
Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
The Proportion of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs
Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
The Proportion of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs
Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
The Proportion of Infusions Associated With One or More AEs Related to the Study Product
Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Recruitment was conducted in the U.S., Canada, and Europe at 17 study sites. The first participant was enrolled in August 2008.
| Milestone | IGIV, 10% Then Placebo (During Cross-Over Periods) | Placebo Then IGIV, 10% (During Cross-Over Periods) |
|---|---|---|
| Started | 22 | 22 |
| Completed | 22 | 21 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | IGIV, 10% Then Placebo (During Cross-Over Periods) | Placebo Then IGIV, 10% (During Cross-Over Periods) |
|---|---|---|
| Started | 22 | 21 |
| Completed | 22 | 21 |
| Not completed | 0 | 0 |
| Milestone | IGIV, 10% Then Placebo (During Cross-Over Periods) | Placebo Then IGIV, 10% (During Cross-Over Periods) |
|---|---|---|
| Started | 22 | 21 |
| Completed | 22 | 21 |
| Not completed | 0 | 0 |
| Milestone | IGIV, 10% Then Placebo (During Cross-Over Periods) | Placebo Then IGIV, 10% (During Cross-Over Periods) |
|---|---|---|
| Started | 22 | 21 |
| Completed | 21 | 21 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | IGIV, 10% Then Placebo (During Cross-Over Periods) | Placebo Then IGIV, 10% (During Cross-Over Periods) |
|---|---|---|
| Started | 21 | 21 |
| Completed | 21 | 20 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | IGIV, 10% Then Placebo (During Cross-Over Periods) | Placebo Then IGIV, 10% (During Cross-Over Periods) |
|---|---|---|
| Started | 22 | 22 |
| Completed | 22 | 22 |
| Not completed | 0 | 0 |
The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. Each grip strength test consisted of 3 maximal repeated contractions (trials). Each participant will perform 2 sessions of grip strength testing. After a 10-minute break, the testing session will be repeated for a total of 6 grip repetitions per hand.
| kilograms | Before Stabilization 1 | End of Stabilization 1 | End of Cross-Over 1 | End of Stabilization 2 | End of Cross-Over 2 | End of Stabilization 3 | End of the Study |
|---|---|---|---|---|---|---|---|
| IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21) | 18.14 (9.30 to 30.43) | 21.68 (14.05 to 30.83) | 19.54 (10.15 to 29.15) | 19.39 (12.75 to 33.25) | 11.28 (5.50 to 25.92) | 17.77 (9.23 to 27.07) | 17.37 (10.80 to 29.03) |
| Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22) | 13.17 (5.30 to 20.08) | 14.17 (8.08 to 27.47) | 8.38 (4.86 to 17.03) | 14.18 (7.60 to 27.35) | 15.98 (10.73 to 29.65) | 14.28 (9.47 to 28.25) | 14.00 (7.48 to 24.82) |
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.
| Percent change in grip strength | Arm 1: IGIV, 10% Then Placebo- Crossover Period 1 | Arm 1: IGIV, 10% Then Placebo- Crossover Period 2 | Arm 2: Placebo Then IGIV, 10% - Crossover Period 1 | Arm 2: Placebo Then IGIV, 10% - Crossover Period 2 |
|---|---|---|---|---|
| Mean Relative Change in Grip Strength in the More Affected Hand | -16.36 (-30.92 to -1.80) | -30.52 (-43.68 to -17.36) | -30.11 (-48.41 to -11.81) | 23.86 (-23.11 to 70.83) |
Relative grip strength change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.
| Percentage of participants | Decline Only During IGIV, 10% | Decline Only During Placebo | Decline During Both Placebo and IGIV, 10% | No Decline During Placebo or IGIV, 10% |
|---|---|---|---|---|
| Percentage of Participants With at Least a 30% Decline in Relative Grip Strength in the More Affected Hand (Measured Using a DynEx Digital Dynamometer) | 4.8 | 42.9 | 4.8 | 47.6 |
The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. Each grip strength test consisted of 3 maximal repeated contractions (trials). Each participant will perform 2 sessions of grip strength testing. After a 10-minute break, the testing session will be repeated for a total of 6 grip repetitions per hand.
| kilograms | Before Stabilization 1 | End of Stabilization 1 | End of Cross-Over 1 | End of Stabilization 2 | End of Cross-Over 2 | End of Stabilization 3 | End of the Study |
|---|---|---|---|---|---|---|---|
| IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21) | 27.98 (22.35 to 36.35) | 29.52 (23.28 to 36.98) | 29.79 (20.48 to 37.88) | 29.17 (21.68 to 37.70) | 26.58 (13.67 to 32.83) | 28.97 (15.95 to 34.38) | 29.68 (14.72 to 34.35) |
| Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22) | 27.23 (18.73 to 34.45) | 28.23 (19.72 to 36.80) | 20.28 (9.61 to 33.44) | 26.92 (17.52 to 37.72) | 27.35 (21.58 to 37.12) | 25.72 (20.18 to 36.55) | 24.98 (16.02 to 35.85) |
Relative Change is defined as 100 \* (End of the Cross-Over Period - Baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.
| Percent change in grip strength | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 | Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 | Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 |
|---|---|---|---|---|
| Mean Relative Change in Grip Strength in the Less Affected Hand | -2.52 (-7.90 to 2.85) | -17.96 (-29.81 to -6.10) | -29.22 (-40.62 to -17.83) | 19.67 (-10.84 to 50.17) |
Participants were permitted to switch from blinded treatment with placebo or IGIV, 10% to open label IGIV, 10% if they and investigator agreed that deterioration had occurred to the extent that the participant had unacceptable difficulty carrying out daily activities involving the affected muscles, or decline in grip strength of ≥50% in the more affected hand had occurred.
| Proportion of participants | Accelerated Switch During IGIV, 10% and Placebo | Accelerated Switch During Placebo, But Not IGIV, 10% | Accelerated Switch During IGIV, 10%, But Not Placebo | No Accelerated Switch During IGIV, 10% or Placebo |
|---|---|---|---|---|
| Proportion of Participants That Were Accelerated Forward Into the Next Stabilization Phase (ie Switched to Open-Label IGIV, 10%) | 0.0 | 69.0 | 2.4 | 28.6 |
Patient Global Impression of Change was measured on an ordinal scale of 1-7, higher scores representing greater perceived deterioration since the previous efficacy assessment (ranging from (1) very much improved to very much worse (7)). 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse
| Scores on a scale | End of Stabilization 1 | End of Cross-Over 1 | End of Stabilization 2 | End of Cross-Over 2 | End of Stabilization 3 | End of the Study |
|---|---|---|---|---|---|---|
| IGIV, 10% then Placebo (N= 22, 22, 22, 21, 17, 21) | 4.0 (3.0 to 4.0) | 4.0 (4.0 to 4.0) | 4.0 (4.0 to 4.0) | 5.0 (5.0 to 6.0) | 2.0 (2.0 to 4.0) | 4.0 (3.0 to 4.0) |
| Placebo then IGIV, 10% (N= 22, 20, 21, 21, 19, 22) | 4.0 (3.0 to 4.0) | 6.0 (5.0 to 6.0) | 3.0 (2.0 to 3.0) | 4.0 (3.0 to 4.0) | 4.0 (4.0 to 4.0) | 4.0 (4.0 to 4.0) |
The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability. Overall disability sum score = arm disability scale (range 0-5) + leg disability scale (range 0-7); Overall Range: 0 (no signs of disability) to 12 (maximum disability).
| Scores on a scale | Before Stabilization 1 | End of Stabilization 1 | End of Cross-Over 1 | End of Stabilization 2 | End of Cross-Over 2 | End of Stabilization 3 | End of the Study |
|---|---|---|---|---|---|---|---|
| IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21) | 3 (2 to 4) | 2 (2 to 4) | 3 (2 to 4) | 2 (2 to 4) | 3 (2 to 4) | 2 (2 to 4) | 2 (2 to 4) |
| Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22) | 3 (2 to 4) | 3 (2 to 4) | 4 (3 to 5) | 3 (2 to 4) | 3 (2 to 4) | 4 (2 to 4) | 3 (2 to 4) |
The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability. Overall disability sum score = arm disability scale (range 0-5) + leg disability scale (range 0-7); Overall Range: 0 (no signs of disability) to 12 (maximum disability). This was standardized to a scale of 0 to 100 (the best score being 100) to allow calculation of relative changes.
| Scores on a scale | Before Stabilization 1 | End of Stabilization 1 | End of Cross-Over 1 | End of Stabilization 2 | End of Cross-Over 2 | End of Stabilization 3 | End of the Study |
|---|---|---|---|---|---|---|---|
| IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21) | 75.0 (66.7 to 83.3) | 83.3 (66.7 to 83.3) | 79.2 (66.7 to 83.3) | 83.3 (66.7 to 83.3) | 75.0 (66.7 to 83.3) | 83.3 (66.7 to 83.3) | 83.3 (66.7 to 83.3) |
| Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22) | 75.0 (66.7 to 83.3) | 75.0 (66.7 to 83.3) | 66.7 (58.3 to 75.0) | 75.0 (66.7 to 83.3) | 75.0 (66.7 to 83.3) | 66.7 (66.7 to 83.3) | 75.0 (66.7 to 83.3) |
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability (from 0, "no signs of disability" to 12, "most severe disability"). This was standardized to a scale of 0 to 100 (the best score being 100) to allow calculation of relative changes.
| percent change in score | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 | Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 | Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 |
|---|---|---|---|---|
| Mean Relative Change in Overall Disability Sum Score | -3.14 (-6.55 to 0.27) | -5.77 (-10.33 to -1.20) | -8.46 (-12.81 to -4.11) | 0.92 (-2.88 to 4.73) |
The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.
| Seconds | Before Stabilization 1 | End of Stabilization 1 | End of Cross-Over 1 | End of Stabilization 2 | End of Cross-Over 2 | End of Stabilization 3 | End of the Study |
|---|---|---|---|---|---|---|---|
| IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21) | 20.75 (19.50 to 27.50) | 22.00 (19.50 to 29.00) | 20.25 (18.00 to 29.00) | 21.00 (18.00 to 24.50) | 20.50 (18.50 to 27.50) | 20.50 (19.00 to 24.50) | 20.00 (19.00 to 25.50) |
| Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22) | 26.75 (20.50 to 39.00) | 25.25 (19.00 to 33.50) | 27.75 (23.00 to 43.50) | 24.50 (19.00 to 34.50) | 25.00 (20.00 to 30.50) | 27.50 (20.50 to 35.50) | 26.25 (19.50 to 33.00) |
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.
| Percent change in time | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 | Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 | Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 |
|---|---|---|---|---|
| Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand | -2.57 (-9.99 to 4.86) | 3.90 (-4.59 to 12.39) | 29.89 (12.46 to 47.31) | 4.89 (-9.45 to 19.23) |
The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their non-dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.
| Seconds | Before Stabilization 1 | End of Stabilization 1 | End of Cross-Over 1 | End of Stabilization 2 | End of Cross-Over 2 | End of Stabilization 3 | End of the Study |
|---|---|---|---|---|---|---|---|
| IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21) | 25.75 (20.00 to 29.50) | 22.50 (19.50 to 27.00) | 24.00 (19.50 to 28.50) | 23.50 (19.50 to 27.00) | 25.25 (22.50 to 29.50) | 21.00 (19.50 to 24.50) | 23.00 (20.50 to 26.50) |
| Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22) | 31.25 (22.50 to 51.00) | 28.00 (22.50 to 40.00) | 37.25 (26.25 to 82.75) | 31.50 (24.00 to 38.50) | 32.50 (22.00 to 41.00) | 30.00 (22.50 to 39.50) | 30.00 (21.00 to 38.50) |
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their non-dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.
| Percent change in time | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 | Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 | Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 |
|---|---|---|---|---|
| Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand | 4.78 (-1.65 to 11.21) | 13.06 (4.46 to 21.65) | 52.93 (26.82 to 79.05) | 8.56 (-4.88 to 22.01) |
The VAS measured patients' assessment of physical functioning on a 10 centimeter scale of 0-10, on which 0 represents "no symptoms" and 10 "disabled, unable to use affected limbs".
| Scores on a scale | Before Stabilization 1 | End of Stabilization 1 | End of Cross-Over 1 | End of Stabilization 2 | End of Cross-Over 2 | End of Stabilization 3 | End of the Study |
|---|---|---|---|---|---|---|---|
| IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21) | 4.80 (2.90 to 6.30) | 2.95 (1.60 to 5.10) | 4.10 (2.00 to 5.60) | 3.50 (1.70 to 5.10) | 6.85 (5.90 to 8.10) | 4.50 (2.60 to 5.10) | 3.70 (1.90 to 5.40) |
| Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22) | 4.95 (2.30 to 7.60) | 3.15 (2.70 to 5.50) | 7.15 (6.75 to 7.60) | 5.10 (2.30 to 6.10) | 4.60 (2.40 to 5.90) | 4.50 (2.60 to 6.00) | 5.15 (2.80 to 6.30) |
Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The VAS measured patients' assessment of physical functioning on a 10 centimeter scale of 0-10, on which 0 represents "no symptoms" and 10 "disabled, unable to use affected limbs".
| Percent change in assessment | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 | Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 | Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 |
|---|---|---|---|---|
| Mean Relative Change in Participants' Assessment of Physical Functioning on a Visual Analog Scale (VAS) | 140.92 (-1.35 to 283.19) | 321.75 (-73.45 to 716.95) | 258.09 (-100.83 to 617.01) | 5.75 (-11.54 to 23.04) |
GNDS (based on Sharrack and Hughes, 1999) for the upper limbs were integers 0 to 5, with 0 indicating no impairment.
| Scores on a scale | Before Stabilization 1 | End of Stabilization 1 | End of Cross-Over 1 | End of Stabilization 2 | End of Cross-Over 2 | End of Stabilization 3 | End of the Study |
|---|---|---|---|---|---|---|---|
| IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21) | 2.0 (2.0 to 3.0) | 2.0 (2.0 to 2.0) | 2.0 (2.0 to 2.0) | 2.0 (2.0 to 3.0) | 2.5 (2.0 to 3.0) | 2.0 (2.0 to 2.0) | 2.0 (2.0 to 2.0) |
| Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22) | 2.0 (2.0 to 3.0) | 2.0 (2.0 to 3.0) | 2.0 (2.0 to 3.0) | 2.0 (1.0 to 3.0) | 2.0 (2.0 to 3.0) | 2.0 (2.0 to 3.0) | 2.0 (2.0 to 3.0) |
Relative grip strength change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.
| Proportion of participants | Decline Only During IGIV, 10% | Decline Only During Placebo | Decline During Both Placebo and IGIV, 10% | No Decline During Placebo and IGIV, 10% |
|---|---|---|---|---|
| Proportion of Participants With at Least a 30% Decline in Relative Grip Strength in the Less Affected Hand (Measured Using a DynEx Digital Dynamometer) | 0.0 | 31.0 | 2.4 | 66.7 |
GNDS (based on Sharrack and Hughes, 1999) for the upper limbs were integers 0 to 5, with 0 indicating no impairment.
| Proportion of participants | Deterioration After IGIV, 10% and Placebo | Deterioration After Placebo, But Not IGIV, 10% | Deterioration After IGIV, 10%, But Not Placebo | No Deterioration After IGIV, 10% or Placebo |
|---|---|---|---|---|
| Co-Primary Endpoint: Proportion of Participants With Deterioration in Guy's Neurological Disability Score (GNDS) | 4.8 (2.0 to 2.0) | 35.7 (2.0 to 3.0) | 11.9 (2.0 to 3.0) | 47.6 (2.0 to 3.0) |
The total number of all AEs which begin during or within 72 hours of completion of an infusion, irrespective of being related or not related to the study product (IGIV, 10% or Placebo), divided by the total number of infusions, and multiplied by 100.
| Percentage of AEs per infusion | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Period | Arm 1: IGIV, 10% Then Placebo- Placebo Period | Arm 2: Placebo Then IGIV, 10%- Placebo Period | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Period |
|---|---|---|---|---|
| Rate of Temporally Associated Adverse Events (AEs) Per Infusion | 11.5 | 13.2 | 24.6 | 11.6 |
| percentage of participants | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Period | Arm 1: IGIV, 10% Then Placebo- Placebo Period | Arm 2: Placebo Then IGIV, 10%- Placebo Period | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Period |
|---|---|---|---|---|
| The Percentage of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason | 9.1 | 0.0 | 4.8 | 4.8 |
| percentage of infusions | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Period | Arm 1: IGIV, 10% Then Placebo- Placebo Period | Arm 2: Placebo Then IGIV, 10%- Placebo Period | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Period |
|---|---|---|---|---|
| The Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason | 2.9 | 0.0 | 1.6 | 0.7 |
The total number of AEs determined by the investigator to be related to the study product that occur at any time during the study divided by the total number of infusions, and multiplied by 100.
| AEs per infusion | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Period | Arm 1: IGIV, 10% Then Placebo- Placebo Period | Arm 2: Placebo Then IGIV, 10%- Placebo Period | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Period |
|---|---|---|---|---|
| Rate of Related AEs Per Infusion | 4.8 | 20.6 | 44.3 | 15.9 |
The total number of SAEs determined by the investigator to be related to the study product that occur at any time during the study divided by the total number of infusions, and multiplied by 100.
| SAEs per infusion | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Period | Arm 1: IGIV, 10% Then Placebo- Placebo Period | Arm 2: Placebo Then IGIV, 10%- Placebo Period | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Period |
|---|---|---|---|---|
| Rate of Related SAEs Per Infusion | 0.0 | 0.0 | 0.0 | 0.7 |
| proportion of participants | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Period | Arm 1: IGIV, 10% Then Placebo- Placebo Period | Arm 2: Placebo Then IGIV, 10%- Placebo Period | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Period |
|---|---|---|---|---|
| The Proportion of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs | 0.0 | 0.0 | 0.0 | 4.8 |
| proportion of infusions | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Period | Arm 1: IGIV, 10% Then Placebo- Placebo Period | Arm 2: Placebo Then IGIV, 10%- Placebo Period | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Period |
|---|---|---|---|---|
| The Proportion of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs | 0.0 | 0.0 | 0.0 | 0.7 |
| proportion of infusions | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Period | Arm 1: IGIV, 10% Then Placebo- Placebo Period | Arm 2: Placebo Then IGIV, 10%- Placebo Period | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Period |
|---|---|---|---|---|
| The Proportion of Infusions Associated With One or More AEs Related to the Study Product | 3.8 | 19.1 | 34.4 | 13.0 |
| percentage of participants | Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Period | Arm 1: IGIV, 10% Then Placebo- Placebo Period | Arm 2: Placebo Then IGIV, 10%- Placebo Period | Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Period |
|---|---|---|---|---|
| The Percentage of Participants Reporting One or More Moderate or Severe AEs That Began During Infusion or Within 72 Hours of Completion of an Infusion | 4.5 | 27.3 | 19.0 | 4.8 |
Collected over Throughout the study period, approximately three years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGIV, 10% | — | 2/44 (4.5%) | 35/44 (79.5%) |
| Placebo | — | 0/43 (0%) | 33/43 (76.7%) |
| Event | IGIV, 10% | Placebo |
|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/44 | 0/43 |
| Vision blurredEye disorders | 1/44 | 0/43 |
| Event | IGIV, 10% | Placebo |
|---|---|---|
| NEUROLOGICAL DECOMPENSATIONNervous system disorders | 10/44 | 25/43 |
| HEADACHENervous system disorders | 16/44 | 2/43 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 9/44 | 0/43 |
| MUSCLE SPASMSMusculoskeletal and connective tissue disorders | 8/44 | 2/43 |
| INFLUENZA LIKE ILLNESSGeneral disorders | 7/44 | 1/43 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 7/44 | 0/43 |
| MUSCULAR WEAKNESSMusculoskeletal and connective tissue disorders | 6/44 | 2/43 |
| BACK PAINMusculoskeletal and connective tissue disorders | 5/44 | 1/43 |
| CONTUSIONInjury, poisoning and procedural complications | 5/44 | 2/43 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 4/44 | 3/43 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 51.64 ± 10.25 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 12 |
| Male | 32 |
Ran from Aug 2008 to primary completion in Aug 2011, 35 months.
Results were first posted in Mar 2013, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous